蒙药清肝九味散治疗酒精性肝炎的效果观察

戈宏焱; 赵百岁; 张仕华; 苏雅

doi:10.3969/j.issn.1001-5256.2016.10.026

蒙药清肝九味散治疗酒精性肝炎的效果观察

DOI: 10.3969/j.issn.1001-5256.2016.10.026

1. 内蒙古民族大学附属医院消化内科
2. 内蒙古民族大学临床医学院
3. 内蒙古民族大学

基金项目:

内蒙古自然科学基金面上项目(2015MS0805)；

详细信息

中图分类号: R29
计量
- 文章访问数: 2626
- HTML全文浏览量: 23
- PDF下载量: 447
- 被引次数: 0
出版历程
- 出版日期: 2016-10-20

Clinical effect of Mongolian drug Qinggan Jiuwei powder in treatment of alcoholic hepatitis

Department of Gastroenterology, Affiliated Hospital of Inner Mongolia University for The Nationalities

Research funding:

摘要

摘要:
目的观察蒙药清肝九味散对酒精性肝炎患者的治疗作用。方法收集内蒙古民族大学附属医院2014年5月-2016年4月收治的酒精性肝炎患者63例,随机分为试验组（32例）和对照组（31例）。试验组给予蒙药清肝九味散治疗;对照组31例给予还原型谷胱甘肽片治疗。2组患者均治疗4周并在此期间均严格戒酒、卧床休息。计量资料组间比较采用t检验。结果对照组患者肝功能指标（ALT、AST、GGT）治疗后与治疗前比较均有明显改善[（38.7±13.3）U/L vs（77.5±16.7）U/L)、（43.8±21.8）U/L vs（176.6±40.1）U/L、（63.8±21.7）U/L vs（302.9±73.3）U/L,t值分别为10.21、16.90、17.40,P值均<0.01];试验组患者治疗后与治疗前比较亦有明显改善[（37.6±14.6）U/L vs（78.1±17.5）U/L、（39.6±15.3）U/L vs（180.3±44.3）U/L、（59.9±23.8）U/L vs（304.7±66.5）U/L,t值分别为10.10、16.40、19.60,P值均<0.01]。对照组患者...
- 肝炎,酒精性 /
- 蒙药 /
- 治疗结果
Abstract:
Objective To investigate the clinical effect of Mongolian drug Qinggan Jiuwei powder in the treatment of patients with alcoholic hepatitis. Methods A total of 63 patients with alcoholic hepatitis who were admitted to Affiliated Hospital of Inner Mongolia University for The Nationalities from May 2014 to April 2016 were enrolled. The 32 patients in the trial group were given Mongolian drug Qinggan Jiuwei powder,and the 31 patients in the control group were given reduced glutathione tablets. The course of treatment was 4 weeks for both groups,and the patients were asked to quit drinking,stay in bed,and have a rest. The t-test was used for the comparison of continuous data between groups. Results After treatment,the control group showed significant improvements in the liver function parameters alanine aminotransferase( ALT),aspartate aminotransferase( AST),and gamma-glutamyl transpeptidase( GGT)( ALT: 38. 7 ± 13. 3 U / L vs 77. 5 ±16. 7 U / L,t = 10. 21,P < 0. 01; AST: 43. 8 ± 21. 8 U / L vs 176. 6 ± 40. 1 U / L,t = 16. 90,P < 0. 01; GGT: 63. 8 ± 21. 7 U / L vs 302. 9 ±73. 3 U / L,t = 17. 40,P < 0. 01); the trial group also showed significant improvements in these parameters( ALT: 37. 6 ± 14. 6 U / L vs78. 1 ± 17. 5 U / L,t = 10. 10,P < 0. 01; AST: 39. 6 ± 15. 3 U / L vs 180. 3 ± 44. 3 U / L,t = 16. 40,P < 0. 01; GGT: 59. 9 ± 23. 8 U / L vs304. 7 ± 66. 5 U / L,t = 19. 60,P < 0. 01). After treatment,the control group showed significant improvements in the serum liver fibrosis parameters hyaluronic acid,precollagen type Ⅲ,laminin,and collagen type Ⅳ( hyaluronic acid: 122. 1 ± 36. 2 ng / ml vs 369. 2 ± 139. 8ng / ml,t = 9. 52,P < 0. 05; precollagen type Ⅲ: 118. 6 ± 43. 8 ng / ml vs 185. 9 ± 92. 7 ng / ml,t = 3. 66,P < 0. 05; laminin: 137. 2 ±49. 9 ng / ml vs 166. 1 ± 50. 4 ng / ml,t = 2. 24,P < 0. 05; collagen type Ⅳ: 128. 7 ± 48. 3 ng / ml vs 155. 1 ± 44. 5 ng / ml,t = 2. 27,P <0. 05); the trial group also showed significant improvements in these parameters( hyaluronic acid: 101. 1 ± 27. 9 ng / ml vs 367. 4 ± 149. 7ng / ml,t = 9. 88,P < 0. 01; precollagen type Ⅲ: 91. 6 ± 48. 4 ng / ml vs 188. 3 ± 100. 5 ng / ml,t = 4. 95,P < 0. 01; laminin: 94. 8 ± 34. 6ng / ml vs 167. 6 ± 48. 7 ng / ml,t = 5. 61,P < 0. 01; collagen type Ⅳ: 92. 7 ± 30. 3 ng / ml vs 161. 3 ± 62. 2 ng / ml,t = 6. 87,P < 0. 01).There were significant differences in the liver function parameters after treatment between the two groups( t = 2. 53,2. 31,3. 56,and 3. 90,all P < 0. 05). Conclusion The Mongolian drug Qinggan Jiuwei powder can improve liver function and reduce liver fibrosis parameters in patients with alcoholic hepatitis.
- hepatitis /
- alcoholic /
- mongolian drugs

HTML全文

参考文献(13)

[1]QI F,CHEN LY,SUN YL.Protective effect of Lingxu liver-protecting tablets on alcohol-induced liver injury[J].J Changchun Univ Tradit Chin Med,2015,31(2):232-234.(in Chinese)綦菲,陈丽艳,孙银玲.灵须护肝片对急性酒精性的保护作用[J].长春中医药大学学报,2015,31(2):232-234.

[2] The Chinese National Workshop on Fatty Liver and Alcoholic Liver Disease for the Chinese Liver Disease Association.Guidelines for management of alcoholic liver disease:an up dated and revised edition[J].Chin J Hepatol,2010,18(3):167-170.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南(2010年修订版)[J].中华肝脏病杂志,2010,18(3):167-170.

[3]GE JB,XU YJ.Internal medicine[M].Beijing:People's Medical Publishing House,2014:409,419.(in Chinese)葛均波,徐永健.内科学[M].北京:人民卫生出版社,2014:409,419.

[4]European Association for the Study of Liver.EASL clinical practical guidelines:management of alcoholic liver disease[J].J Hepatol,2012,57(2):399-420.

[5]CHANG BX,WANG H,ZOU ZS,et al.Pathogenesis and novel therapeutic targets of alcoholic liver disease[J].J Clin Hepatol,2014,30(2):113-117.(in Chinese)常彬霞,王华,邹正升,等.酒精性肝病的发病机理和新的治疗靶点[J].临床肝胆病杂志,2014,30(2):113-117.

[6]NEUMAN MG,FRENCH SW,FRENCH BA,et al.Alcoholic and non-alcoholic steatohepatitis[J].Exp Mol Pathol,2014,97(3):492-510.

[7]ROTH N,KANEL G,KAPLOWITZ N.Alcoholic foamy degeneration and alcoholic fatty liver with jaundice:often overlooked causes of jaundice and hepatic decompensation that can mimic alcoholic hepatitis[J].Clin Liver Dis,2015,6(6):145-148.

[8]WANG XB,SUN L.Progress and prospect of diagnosis and treatment of hepatic fibrosis by integrated traditional Chinese and Western medicine therapy[J].J Clin Hepatol,2015,31(1):38-41.(in Chinese)王宪波,孙乐.肝纤维化的中西医结合诊治[J].临床肝胆病杂志,2015,31(1):38-41.

[9]FINELLI C,TARANTINO G.Non-alcoholic fatty liver disease,diet and gut microbiota[J].EXCLI J,2014,13:461-490.

[10]DUFFIELD JS,LUPHER M,THANNICKAL VJ,et al.Host responses in tissue repair and fibrosis[J].Annu Rev Pathol,2013,8(4):241-276.

[11]XIAO G,YAN L.Liver Fibrosis and its assessment[M]//Operative techniques in liver resection.Germany:Springer Netherlands,2016:43-52.

[12]CHALASANI N,YOUNOSSI Z,LAVINE JE,et al.The diagnosis and management of non-alcoholic fatty liver disease:Practice Guideline by the American Association for the Study of Liver Diseases,American College of Gastroenterology,and the American Gastroenterological Association[J].Hepatology,2012,55(6):2005-2023.

[13]LIANG XE,WANG Y,HOU JL.Quantitative assessment of liver fibrosis:invasive or non-invasive?[J].J Clin Hepatol,2015,31(3):317-321.(in Chinese)梁携儿,汪艳,侯金林.肝纤维化定量诊断:有创还是无创?[J].临床肝胆病杂志,2015,31(3):317-321.

施引文献

资源附件(0)

访问统计